RaySearch Laboratories AB (publ) Logo

RaySearch Laboratories AB (publ)

RAY-B.ST

(1.5)
Stock Price

165,60 SEK

4.77% ROA

11.63% ROE

48.4x PER

Market Cap.

3.119.994.556,00 SEK

71.41% DER

0% Yield

7.98% NPM

RaySearch Laboratories AB (publ) Stock Analysis

RaySearch Laboratories AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

RaySearch Laboratories AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE falls within an average range (7.91%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (3.86%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

3 DER

The stock maintains a fair debt to equity ratio (76%), indicating a reasonable balance between the money it owes and the ownership it possesses.

4 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

5 Net Profit Growth

This company's net profit has been consistently on the rise over the past three years, indicating a strong financial performance and making it an appealing investment opportunity.

6 Buffet Intrinsic Value

The company's stock seems undervalued (2.748) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

7 PBV

The stock's elevated P/BV ratio (4.71x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

RaySearch Laboratories AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

RaySearch Laboratories AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

RaySearch Laboratories AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

RaySearch Laboratories AB (publ) Revenue
Year Revenue Growth
2003 22.145.000
2004 39.479.000 43.91%
2005 69.855.000 43.48%
2006 68.976.000 -1.27%
2007 64.705.000 -6.6%
2008 62.690.000 -3.21%
2009 83.687.000 25.09%
2010 117.728.000 28.91%
2011 126.103.000 6.64%
2012 182.087.000 30.75%
2013 204.470.000 10.95%
2014 285.217.000 28.31%
2015 397.600.000 28.27%
2016 531.468.000 25.19%
2017 585.086.000 9.16%
2018 627.219.000 6.72%
2019 741.584.000 15.42%
2020 651.612.000 -13.81%
2021 641.673.000 -1.55%
2022 843.648.000 23.94%
2023 1.011.532.000 16.6%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

RaySearch Laboratories AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2003 3.302.000
2004 10.803.000 69.43%
2005 11.052.000 2.25%
2006 11.561.000 4.4%
2007 24.225.000 52.28%
2008 29.183.000 16.99%
2009 24.718.000 -18.06%
2010 53.500.000 53.8%
2011 57.575.000 7.08%
2012 78.657.000 26.8%
2013 90.720.000 13.3%
2014 95.069.000 4.57%
2015 101.514.000 6.35%
2016 93.207.000 -8.91%
2017 104.304.000 10.64%
2018 147.691.000 29.38%
2019 174.670.000 15.45%
2020 185.041.000 5.6%
2021 233.443.000 20.73%
2022 238.769.000 2.23%
2023 245.404.000 2.7%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

RaySearch Laboratories AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 8.915.000
2004 10.995.000 18.92%
2005 11.168.000 1.55%
2006 11.572.000 3.49%
2007 12.525.000 7.61%
2008 11.031.000 -13.54%
2009 12.691.000 13.08%
2010 17.756.000 28.53%
2011 21.369.000 16.91%
2012 39.279.000 45.6%
2013 80.108.000 50.97%
2014 30.736.000 -160.63%
2015 43.240.000 28.92%
2016 66.291.000 34.77%
2017 63.247.000 -4.81%
2018 91.983.000 31.24%
2019 100.135.000 8.14%
2020 106.290.000 5.79%
2021 122.036.000 12.9%
2022 171.719.000 28.93%
2023 171.408.000 -0.18%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

RaySearch Laboratories AB (publ) EBITDA
Year EBITDA Growth
2003 9.004.000
2004 15.042.000 40.14%
2005 45.224.000 66.74%
2006 40.835.000 -10.75%
2007 28.351.000 -44.03%
2008 24.155.000 -17.37%
2009 41.287.000 41.49%
2010 40.125.000 -2.9%
2011 28.731.000 -39.66%
2012 72.101.000 60.15%
2013 28.130.000 -156.31%
2014 133.674.000 78.96%
2015 145.618.000 8.2%
2016 266.594.000 45.38%
2017 228.058.000 -16.9%
2018 207.046.000 -10.15%
2019 252.348.000 17.95%
2020 213.218.000 -18.35%
2021 197.363.000 -8.03%
2022 340.853.000 42.1%
2023 114.464.000 -197.78%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

RaySearch Laboratories AB (publ) Gross Profit
Year Gross Profit Growth
2003 20.392.000
2004 38.241.000 46.68%
2005 68.734.000 44.36%
2006 68.127.000 -0.89%
2007 63.842.000 -6.71%
2008 62.029.000 -2.92%
2009 82.674.000 24.97%
2010 117.636.000 29.72%
2011 125.661.000 6.39%
2012 179.058.000 29.82%
2013 198.411.000 9.75%
2014 273.590.000 27.48%
2015 373.910.000 26.83%
2016 504.596.000 25.9%
2017 548.436.000 7.99%
2018 571.195.000 3.98%
2019 669.219.000 14.65%
2020 608.238.000 -10.03%
2021 591.276.000 -2.87%
2022 748.657.000 21.02%
2023 888.196.000 15.71%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

RaySearch Laboratories AB (publ) Net Profit
Year Net Profit Growth
2003 -5.023.000
2004 12.903.000 138.93%
2005 29.142.000 55.72%
2006 36.219.000 19.54%
2007 19.779.000 -83.12%
2008 18.223.000 -8.54%
2009 30.146.000 39.55%
2010 28.895.000 -4.33%
2011 17.007.000 -69.9%
2012 19.863.000 14.38%
2013 -20.841.000 195.31%
2014 59.832.000 134.83%
2015 70.209.000 14.78%
2016 151.408.000 53.63%
2017 117.627.000 -28.72%
2018 78.523.000 -49.8%
2019 50.411.000 -55.77%
2020 -9.080.000 655.19%
2021 -47.315.000 80.81%
2022 23.778.000 298.99%
2023 86.204.000 72.42%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

RaySearch Laboratories AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 0
2004 0 0%
2005 1 0%
2006 1 100%
2007 1 0%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 -1 0%
2014 2 100%
2015 2 50%
2016 4 50%
2017 3 -33.33%
2018 2 -50%
2019 1 -100%
2020 0 0%
2021 -1 100%
2022 1 0%
2023 3 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

RaySearch Laboratories AB (publ) Free Cashflow
Year Free Cashflow Growth
2003 1.274.000
2004 945.000 -34.81%
2005 26.806.000 96.47%
2006 13.070.000 -105.1%
2007 35.702.000 63.39%
2008 25.548.000 -39.74%
2009 48.121.000 46.91%
2010 60.385.000 20.31%
2011 31.332.000 -92.73%
2012 33.286.000 5.87%
2013 -25.260.000 231.77%
2014 -7.571.000 -233.64%
2015 7.571.000 200%
2016 13.899.000 45.53%
2017 -1.344.000 1134.15%
2018 -45.162.000 97.02%
2019 108.099.000 141.78%
2020 105.915.000 -2.06%
2021 -17.060.000 720.84%
2022 125.276.000 113.62%
2023 80.705.000 -55.23%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

RaySearch Laboratories AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2003 6.972.000
2004 12.872.000 45.84%
2005 41.393.000 68.9%
2006 30.093.000 -37.55%
2007 37.862.000 20.52%
2008 26.045.000 -45.37%
2009 49.207.000 47.07%
2010 62.785.000 21.63%
2011 33.852.000 -85.47%
2012 87.451.000 61.29%
2013 31.282.000 -179.56%
2014 50.273.000 37.78%
2015 111.426.000 54.88%
2016 120.848.000 7.8%
2017 147.481.000 18.06%
2018 178.472.000 17.36%
2019 320.145.000 44.25%
2020 331.508.000 3.43%
2021 238.162.000 -39.19%
2022 356.777.000 33.25%
2023 124.378.000 -186.85%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

RaySearch Laboratories AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2003 5.698.000
2004 11.927.000 52.23%
2005 14.587.000 18.24%
2006 17.023.000 14.31%
2007 2.160.000 -688.1%
2008 497.000 -334.61%
2009 1.086.000 54.24%
2010 2.400.000 54.75%
2011 2.520.000 4.76%
2012 54.165.000 95.35%
2013 56.542.000 4.2%
2014 57.844.000 2.25%
2015 103.855.000 44.3%
2016 106.949.000 2.89%
2017 148.825.000 28.14%
2018 223.634.000 33.45%
2019 212.046.000 -5.46%
2020 225.593.000 6.01%
2021 255.222.000 11.61%
2022 231.501.000 -10.25%
2023 43.673.000 -430.08%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

RaySearch Laboratories AB (publ) Equity
Year Equity Growth
2003 19.821.000
2004 32.724.000 39.43%
2005 81.854.000 60.02%
2006 118.073.000 30.68%
2007 137.851.000 14.35%
2008 150.435.000 8.37%
2009 184.858.000 18.62%
2010 196.762.000 6.05%
2011 196.697.000 -0.03%
2012 217.553.000 9.59%
2013 196.601.000 -10.66%
2014 251.548.000 21.84%
2015 319.517.000 21.27%
2016 460.188.000 30.57%
2017 580.425.000 20.72%
2018 657.453.000 11.72%
2019 705.468.000 6.81%
2020 694.351.000 -1.6%
2021 649.278.000 -6.94%
2022 657.156.000 1.2%
2023 709.012.000 7.31%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

RaySearch Laboratories AB (publ) Assets
Year Assets Growth
2003 30.756.000
2004 45.418.000 32.28%
2005 107.181.000 57.62%
2006 146.274.000 26.73%
2007 173.233.000 15.56%
2008 188.091.000 7.9%
2009 233.098.000 19.31%
2010 255.926.000 8.92%
2011 260.998.000 1.94%
2012 293.027.000 10.93%
2013 299.162.000 2.05%
2014 389.753.000 23.24%
2015 484.490.000 19.55%
2016 717.254.000 32.45%
2017 915.064.000 21.62%
2018 1.105.422.000 17.22%
2019 1.264.224.000 12.56%
2020 1.284.904.000 1.61%
2021 1.739.038.000 26.11%
2022 1.875.950.000 7.3%
2023 1.866.604.000 -0.5%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

RaySearch Laboratories AB (publ) Liabilities
Year Liabilities Growth
2003 10.935.000
2004 12.694.000 13.86%
2005 25.327.000 49.88%
2006 28.201.000 10.19%
2007 35.382.000 20.3%
2008 37.656.000 6.04%
2009 48.240.000 21.94%
2010 59.164.000 18.46%
2011 64.301.000 7.99%
2012 75.474.000 14.8%
2013 102.561.000 26.41%
2014 138.205.000 25.79%
2015 164.973.000 16.23%
2016 257.066.000 35.82%
2017 334.639.000 23.18%
2018 447.969.000 25.3%
2019 558.756.000 19.83%
2020 590.553.000 5.38%
2021 1.089.760.000 45.81%
2022 1.218.794.000 10.59%
2023 1.157.592.000 -5.29%

RaySearch Laboratories AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
28.79
Net Income per Share
1.87
Price to Earning Ratio
48.4x
Price To Sales Ratio
3.16x
POCF Ratio
6.4
PFCF Ratio
8.1
Price to Book Ratio
4.38
EV to Sales
3.36
EV Over EBITDA
35.96
EV to Operating CashFlow
6.84
EV to FreeCashFlow
8.62
Earnings Yield
0.02
FreeCashFlow Yield
0.12
Market Cap
3,12 Bil.
Enterprise Value
3,32 Bil.
Graham Number
29.51
Graham NetNet
-24.53

Income Statement Metrics

Net Income per Share
1.87
Income Quality
5.74
ROE
0.09
Return On Assets
0.04
Return On Capital Employed
0.09
Net Income per EBT
0.74
EBT Per Ebit
0.94
Ebit per Revenue
0.12
Effective Tax Rate
0.26

Margins

Sales, General, & Administrative to Revenue
0.19
Research & Developement to Revenue
0.23
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.82
Operating Profit Margin
0.12
Pretax Profit Margin
0.11
Net Profit Margin
0.08

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
14.16
Free CashFlow per Share
11.24
Capex to Operating CashFlow
-0.21
Capex to Revenue
-0.1
Capex to Depreciation
0
Return on Invested Capital
0.04
Return on Tangible Assets
0.05
Days Sales Outstanding
0
Days Payables Outstanding
163.14
Days of Inventory on Hand
62.94
Receivables Turnover
0
Payables Turnover
2.24
Inventory Turnover
5.8
Capex per Share
-2.92

Balance Sheet

Cash per Share
8,94
Book Value per Share
20,68
Tangible Book Value per Share
20.68
Shareholders Equity per Share
20.68
Interest Debt per Share
14.9
Debt to Equity
0.71
Debt to Assets
0.27
Net Debt to EBITDA
2.16
Current Ratio
1.21
Tangible Asset Value
0,19 Bil.
Net Current Asset Value
-0,43 Bil.
Invested Capital
0.71
Working Capital
0,12 Bil.
Intangibles to Total Assets
0.28
Average Receivables
0,00 Bil.
Average Payables
0,04 Bil.
Average Inventory
23232000
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

RaySearch Laboratories AB (publ) Dividends
Year Dividends Growth
2008 1
2010 1 0%
2011 1 0%
2016 0 0%

RaySearch Laboratories AB (publ) Profile

About RaySearch Laboratories AB (publ)

RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.

CEO
Dr. Johan Lof
Employee
388
Address
Sveavägen 44
Stockholm, 111 34

RaySearch Laboratories AB (publ) Executives & BODs

RaySearch Laboratories AB (publ) Executives & BODs
# Name Age
1 Mr. Marc Mlyn CMD, MBA
President & Chief Executive Officer of RaySearch Americas
70
2 Mr. Peter Kemlin
Director of Sales & Marketing
70
3 Ms. Tove Alteborg
Global Human Resource Manager
70
4 Mr. Bjorn Hardemark
Deputy Chief Executive Officer
70
5 Ms. Petra Jansson
General Counsel
70
6 Dr. Johan Lof
Founder, Chief Executive Officer, President & Director
70
7 Mr. Fredrik Lofman
Head of Machine Learning
70
8 Ms. Annika Blondeau Henriksson
Interim Chief Financial Officer
70
9 Mr. Kjell Eriksson
Head of Research & Chief Science Officer
70

RaySearch Laboratories AB (publ) Competitors

Elekta AB (publ) Logo
Elekta AB (publ)

EKTA-B.ST

(2.0)
Vitrolife AB (publ) Logo
Vitrolife AB (publ)

VITR.ST

(3.2)
CellaVision AB (publ) Logo
CellaVision AB (publ)

CEVI.ST

(3.5)
Probi AB (publ) Logo
Probi AB (publ)

PROB.ST

(2.0)
Biotage AB (publ) Logo
Biotage AB (publ)

BIOT.ST

(2.8)